Innate Pharma’s patent involves NKp46-binding immunoglobulin variable regions, including antibodies and multispecific proteins that can redirect NK cells to target and destroy specific cells, with applications in treating diseases like cancer and infectious diseases. The patent includes specific isolated nucleic acid sequences for these variable regions. GlobalData’s report on Innate Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Innate Pharma, Personalized cancer vaccines was a key innovation area identified from patents. Innate Pharma's grant share as of February 2024 was 39%. Grant share is based on the ratio of number of grants to total number of patents.
Patent granted for antibodies redirecting nk cells to target cells
A recently granted patent (Publication Number: US11891444B2) discloses an isolated nucleic acid encoding a heavy chain variable region (VH) and/or a light chain variable region (VL) selected from specific sequences. These sequences include various combinations of VH and VL amino acid sequences, such as NKp46-1 H1 or H3 variable domain, NKp46-2 H1, H2, or H3 variable domain, NKp46-3 H1, H3, or H4 variable domain, NKp46-4 H1 variable domain, NKp46-9 H2 or H3 variable domain, and corresponding VL sequences. The patent also covers a recombinant host cell containing the nucleic acid, a method for producing a protein using the cell, and specific variations of the nucleic acid encoding different VH and VL sequences.
Furthermore, the patent includes specific claims related to the nucleic acid sequences encoding the VH and VL regions, such as sequences for NKp46-1, NKp46-2, NKp46-3, NKp46-4, and NKp46-9 variable domains. The claims detail the specific amino acid sequences for the VH and VL regions, providing a comprehensive scope of coverage for the nucleic acid sequences. These claims aim to protect the intellectual property associated with the isolated nucleic acid sequences and their applications in producing proteins through recombinant host cells. Overall, the patent highlights the importance of these specific VH and VL sequences in various biotechnological applications and the potential for developing novel protein products using the disclosed nucleic acid sequences.
To know more about GlobalData’s detailed insights on Innate Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
